Guideline position, pivotal evidence, effect sizes, negative findings — internal hemorrhoids office-based treatment

1. Summary

The domain dossier's §4 already established the AGA's office-first position and the one RCT isolating grade-III rubber band ligation (RBL) durability against surgery; this pass targets what that dossier flagged as unretrieved or unsearched. The ASCRS guideline itself remains paywalled, but a peer-reviewed AAFP summary of it is now retrievable, and it agrees with the AGA's position: office-based banding, sclerotherapy and infrared coagulation are preferred first-line through grade III, with banding "considered the most effective office-based treatment" [1]. Beyond the office-based ladder, the escalation tier this domain competes against on durability — Doppler-guided hemorrhoidal artery ligation (DGHAL) and stapled hemorrhoidopexy — has its own negative finding: a 393-patient multicentre RCT found DGHAL more expensive, slower, and "dominated" on cost-effectiveness at one year despite less pain [3]. A newer, adjacent modality (laser hemorrhoidoplasty) has one small head-to-head trial against RBL at grade II and a five-year follow-up against hemorrhoidectomy and mucopexy, both of which report effect sizes without reaching statistical significance on their primary long-term endpoint [5][6]. No new evidence changes the office-based ladder itself; what changes is that the guideline gap is partially closed and the surgical-escalation comparator set now has sourced effect sizes.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

Guideline position: the ASCRS gap is partially closed

The dossier's §4 could not retrieve either ASCRS hemorrhoid guideline's full text (HTTP 402; an unrenderable PDF mirror). This pass located a peer-reviewed secondary summary of the 2024 ASCRS guideline, published in American Family Physician in December 2025 [1]. It states office-based procedures are "preferred over surgery due to similar benefits with fewer complications," and that "most patients with symptomatic grade I or II hemorrhoids and select patients with grade III hemorrhoids refractory to conservative treatment can be effectively treated with office-based procedures. Hemorrhoid banding is considered the most effective office-based treatment" [1]. This is a summary of the guideline, not the guideline's own text, and no evidence grade for these statements was visible in what was retrieved — mark [single-source]. Read against the AGA's own primary-source language already in the dossier ("Hemorrhoid banding or infrared coagulation should be employed prior to surgical hemorrhoidectomy for grades 1 to 3 hemorrhoids" [2]), the two society positions now agree in substance on the office-first-through-grade-III ladder, stated plainly as a two-source agreement rather than a single-source claim. Neither source specifies a formal evidence grade for the office-based recommendation; the AGA's own BPA statements are explicitly stated to carry none [2], and the ASCRS's grading was not visible in the retrievable summary [1].

Surgical-escalation comparator: DGHAL vs. stapled hemorrhoidopexy — a negative cost-effectiveness finding

The dossier's §4 evidence table stops at RBL vs. hemorrhoidectomy. One tier of escalation this domain's own scope note treats as "surgery" (facility/OR, per the dossier's care-pathway table) has its own controlled comparative literature for grade II-III disease specifically. The LigaLongo trial — a 22-centre, 393-patient RCT (NCT01240772) randomizing grade II/III hemorrhoidal disease to DGHAL (n=197) or circular stapled hemorrhoidopexy (n=196) — found no significant difference in 90-day operative morbidity (24% vs. 26%, p=0.70), but DGHAL took longer (44±16 vs. 30±14 min, p<0.001), produced less pain and shorter sick leave, yet led to "more residual grade III disease (15% vs 5%) and a higher reoperation rate (8% vs 4%)" at one year, cost more (€2806 vs. €2538), and was reported as cost-effectiveness-"dominated" by stapled hemorrhoidopexy at one year [3]. A secondary analysis of the same trial by device brand within each arm found no difference in 90-day morbidity or 12-month grade-III recurrence attributable to which manufacturer's device was used [4]. This is the clearest negative finding located this pass for any energy-based or artery-ligation modality at grade II-III: less pain and faster recovery did not translate into durability, on the trial's own numbers.

An adjacent, newer modality: laser hemorrhoidoplasty

Laser hemorrhoidoplasty (LHP) is not covered anywhere in the dossier's §4 or §5. Two distinct controlled comparisons were located. First, a 70-patient single-centre RCT comparing LHP to RBL at grade II specifically found no difference in one-year recurrence between arms (p>0.05), less postoperative pain and bleeding with LHP in the first two weeks (p<0.01), and faster return to normal activity with LHP (p<0.001) [5]. Second, a double-blind, single-centre RCT (121 patients, grade II-III) randomizing LHP against sutured mucopexy and excisional hemorrhoidectomy reported recurrence requiring treatment at one year of 0% (hemorrhoidectomy), 10% (LHP) and 22% (mucopexy), p=0.004, with LHP and mucopexy less painful than hemorrhoidectomy [6]. Its five-year follow-up (102 of 121 patients reinterviewed) found Kaplan-Meier 5-year symptom recurrence of 24% (hemorrhoidectomy), 29% (LHP) and 44% (mucopexy) — a numeric spread in the same direction as the one-year result, but one that "did not reach statistical significance" (log-rank p=0.076) at five years, in a study its own authors describe as "single- center... with relatively small sample size" [7]. A separate systematic review of laser dearterialization (HeLP, a related but distinct laser technique targeting the feeding artery rather than the hemorrhoidal cushion) found, in the single randomized trial its search identified, symptom resolution in 90% of HeLP patients versus 53.3% of RBL comparators, but rated the overall body of evidence "low" quality by GRADE and noted randomized trials in this space are "rare" [8]. None of the laser literature located this pass isolates grade III specifically the way the dossier's RBL-vs-hemorrhoidectomy trial does [dossier §4], and no laser device's FDA clearance status for a hemorrhoid indication was checked this pass — that remains a gap.

Ongoing registered trials, read as sponsor intentions

Two ClinicalTrials.gov records the dossier's §9/Sources listed by title only were pulled to protocol depth this pass. NCT06170736, sponsored by Centre Hospitalier Departemental Vendee, is recruiting toward an estimated 168 grade II/III patients randomized to radiofrequency ablation vs. DGHAL, primary outcome "failure rate at one year post-operatively"; no results are posted [sponsor-reported] [9]. NCT07333040 (the HELO trial, Chang Gung Memorial Hospital) is a non-randomized, single-masked, ~60-patient (ESTIMATED) pragmatic preference trial comparing laser hemorrhoidoplasty, "Hemorrhoid Energy Therapy," and closed (Ferguson) hemorrhoidectomy at grade III specifically, with a stated 12-month recurrence secondary outcome; no results are posted [sponsor-reported] [10]. Both are registered intentions, not findings, and both target exactly the grade-III durability question the dossier's §4 identifies as the open evidentiary question for this domain.

4. Sources

[1] Management of Hemorrhoids: Guidelines From the ASCRS — American Family Physician (published 2025-12; accessed 2026-09-01). PMID 41533423 — https://www.aafp.org/pubs/afp/issues/2025/1200/practice-guidelines-hemorrhoids.html [guideline] [2] AGA Clinical Practice Update on Diagnosis and Treatment of Hemorrhoids: Expert Review — Clinical Gastroenterology and Hepatology (published 2026, month not given in the PubMed record; accessed 2026-09-01). PMID 42067175 — https://pubmed.ncbi.nlm.nih.gov/42067175/ [guideline] [3] Cost-effectiveness of New Surgical Treatments for Hemorrhoidal Disease: A Multicentre Randomized Controlled Trial Comparing Transanal Doppler-guided Hemorrhoidal Artery Ligation With Mucopexy and Circular Stapled Hemorrhoidopexy — Annals of Surgery (published 2016-11; accessed 2026-09-01). PMID 27741005 — https://pubmed.ncbi.nlm.nih.gov/27741005/ [peer-reviewed] [4] A comparison of surgical devices for grade II and III hemorrhoidal disease. Results from the LigaLongo Trial — International Journal of Colorectal Disease (published 2018-10; accessed 2026-09-01). PMID 29808305 — https://pubmed.ncbi.nlm.nih.gov/29808305/ [peer-reviewed] [5] Laser hemorrhoidoplasty vs. rubber band ligation: a randomized trial comparing 2 mini-invasive treatment for grade II hemorrhoids — BMC Surgery (published 2024-05-27; accessed 2026-09-01). PMID 38797851 — https://pubmed.ncbi.nlm.nih.gov/38797851/ [peer-reviewed] [6] Results of the double-blind randomized controlled trial comparing laser hemorrhoidoplasty with sutured mucopexy and excisional hemorrhoidectomy — International Journal of Colorectal Disease (published 2020-03; accessed 2026-09-01). PMID 31912268 — https://pubmed.ncbi.nlm.nih.gov/31912268/ [peer-reviewed] [7] Five-Year Follow-up of the Double-Blind Randomized Controlled Trial Comparing Laser Hemorrhoidoplasty With Sutured Mucopexy and Excisional Hemorrhoidectomy — Diseases of the Colon & Rectum (published 2026-07-21; accessed 2026-09-01). PMID 42478482 — https://pubmed.ncbi.nlm.nih.gov/42478482/ [peer-reviewed] [8] Hemorrhoid laser dearterialization: systematic review and meta-analysis — Lasers in Medical Science (published 2023-01-25; accessed 2026-09-01). PMID 36695928 — https://pubmed.ncbi.nlm.nih.gov/36695928/ [peer-reviewed] [9] Radiofrequency Ablation vs Doppler-guided Haemorrhoidal Artery Ligation in the Treatment of Haemorrhoidal Disease — ClinicalTrials.gov (registered 2026-03-13; accessed 2026-09-01). NCT06170736 — https://clinicaltrials.gov/study/NCT06170736 [trial-registry] [10] HELO Trial: Energy-Based Therapies vs. Conventional Hemorrhoidectomy for Grade III Hemorrhoids — ClinicalTrials.gov (registered 2026-08-07; accessed 2026-09-01). NCT07333040 — https://clinicaltrials.gov/study/NCT07333040 [trial-registry]

5. Sourcing & Gaps

Well established: the office-first-through-grade-III position, stated plainly with no marker in §3's guideline paragraph, now rests on two independent, non-affiliated society-level sources — the AGA's own primary-source text [2] and a peer-reviewed summary of the ASCRS guideline [1]. Neither is a party to the other's document.

Thin: the DGHAL-vs-stapled-hemorrhoidopexy cost-effectiveness finding [3][4] rests on one trial (two linked publications from the same RCT, so treated as one source for weight) [single-source]. The laser-hemorrhoidoplasty findings [5][6][7] each rest on a single single-centre trial [single-source]; the HeLP systematic review [8] pools mostly non-randomized studies and states its own evidence quality as low. Neither NCT06170736 nor NCT07333040 has posted results — both are marked [sponsor-reported] and their enrollment figures are sponsor-estimated targets, not counts of anyone enrolled.

Rescoped from class 3: none in this report. Every proposition here is a registry fact or a published measured outcome (evidence class 1 or 2); no question about what a clinician or patient would do was posed or answered.

Out of scope: the ASCRS guideline's own primary text (still paywalled/unrenderable, per the dossier's prior attempt — not re-attempted this pass beyond the WebFetch in §3); CPT descriptors; any jurisdiction outside the US and EU; MAUDE (no connector in this repo).

Not searched vs. not found: Not searched this pass — FDA clearance status for any laser hemorrhoidoplasty console or fiber (no 510(k)/classification query was run for this modality); a US-population trial comparing laser hemorrhoidoplasty to RBL or IRC (both located trials [5] are Chinese and Israeli/single-country, respectively, not stated as US); the CLSI-equivalent formal evidence-grading tables for either the AGA or ASCRS statements. Not found — a grade-III-isolated recurrence figure for DGHAL or stapled hemorrhoidopexy comparable in design to the dossier's RBL-vs-hemorrhoidectomy trial (the LigaLongo trial [3][4] pools grade II and III enrollees and reports its 15%-vs-5% "residual grade III" figure across the combined population, not as a grade-III-only subgroup); any evidence grade attached to ASCRS's office-based recommendation in the retrievable AAFP summary [1].

[inference] Treating the LigaLongo trial's arms (DGHAL, stapled hemorrhoidopexy) as the "surgical escalation" tier this domain's own care pathway describes, rather than as alternative office-based procedures, follows the dossier's own care-pathway table (§2: "Escalation to surgery... Facility / OR") rather than any statement in [3] or [4] themselves, neither of which uses the word "office-based."

6. Claim Candidates